|Articles|February 1, 2005

Glaucoma agent lowers IOP by dual mechanism

New Orleans—Travoprost 0.004% (Travatan, Alcon Laboratories) lowers IOP by both increasing outflow facility and improving uveoscleral outflow, according to the results of a clinical study designed to investigate the mechanism of action of travoprost.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME